Rare Diseases Clinical Trials Update: Week 27, 2026

Published July 3, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)

This Phase 2 trial is testing a gene therapy called RGX-202 for boys with Duchenne Muscular Dystrophy, a serious muscle-wasting disease. The therapy aims to address the root cause of the condition and may improve muscle strength and function. The study is recruiting about 65 participants across the US and Canada, offering hope for a new treatment option.

Real-World Effects of MC4R Agonist Therapy in BBS and Severe Genetic Obesity

This Phase 4 study is evaluating the drug setmelanotide for people with Bardet-Biedl Syndrome and other rare genetic obesity disorders. By looking at how well the drug works and its safety in everyday use, the trial could provide important information to help manage severe obesity caused by these rare conditions. The study includes both children and adults and is recruiting in Germany.

A Study to Evaluate the Tolerability, Safety and Efficacy of GNR-097 Gene Therapy in Pediatric Patients With Duchenne Muscular Dystrophy

This early-phase trial is testing a gene therapy called GNR-097 for boys with Duchenne Muscular Dystrophy. The goal is to see if the treatment is safe and can improve muscle function or slow the disease's progression. Recruiting is underway in Belarus and Russia, with 32 participants involved in a placebo-controlled study.

Early Check: Expanded Screening in Newborns

This study offers voluntary screening for several rare genetic conditions in newborns in North Carolina. By identifying conditions like Duchenne Muscular Dystrophy and Fragile X Syndrome early, families may get quicker access to care and support that can improve health and development. The screening uses leftover blood from routine newborn tests and includes genetic counseling.

A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia

This Phase 2 trial tested a weekly injectable treatment called TransCon CNP in children aged 2 to 10 with achondroplasia, a rare bone growth disorder. The trial has completed enrollment with 57 participants in several countries. Results are now available and may offer new options to support growth in affected children.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.